Lipid Management Beyond Statins: Biologic Basis, New Clinical Evidence and Strategies- Enduring Activity


Lipid Management Beyond Statins: Biologic Basis, New Clinical Evidence and Strategies- Enduring Activity

Topic: Cardiology
Primary Audience: Advanced Practice Registered Nurses, Nurse Practitioners, Pharmacists, Physician Assistants, Physicians, Registered Nurses, Registered Dietitians
Launch Date: 13-Aug-15
Credits: 1.25 AMA PRA Category 1 Credits
1.25 ACPE contact hours
1.2 ANCC contact hours
1 CDR continuing professional education unit
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Relate the key biologic pathways responsible for atherosclerotic disease and the mechanisms of therapies that inhibit its development.
  2. Discuss the current clinical trial evidence of therapies that have been used as add-on therapy to statins to reduce CV events.
  3. Incorporate risk assessment, guideline recommendations, and patient-centered approaches for add-on therapeutic decision-making for patients at high risk for CV events.
  4. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families


    Peter Libby, MD, FACC
    Cardiovascular Medicine
    Brigham and Women's Hospital
    Mallinckrodt Professor of Medicine
    Harvard Medical School
    Boston, MA
    Harold E. Bays, MD, FTOS, FACC, FACE, FNLA
    Medical Director / President
    L-MARC Research Center
    Louisville, KY
    Michael Miller, MD, FACC, FAHA
    Professor of Cardiovascular Medicine, Epidemiology & Public Health
    University of Maryland School of Medicine
    Director, Center for Preventive Cardiology
    University of Maryland Medical Center
    Baltimore, MD
    Physicians, Nurse Practitioners, Physician Assistants, pharmacists, Registered Nurses, Advance Practice Registered Nurses, and Registered Dietitians with an interest in lipid management and CV disease risk reduction.
    Statements of credit will be awarded based on the participant’s obtaining a 30% or greater total score on the activity post-test and completion and submission of the activity evaluation form.   If you have questions about this CME/CE activity, please contact the NLA at Please claim credit by August 17, 2016. For Pharmacists: Upon successfully completing the post-test with a score of 30% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks
    This activity is supported by an educational grant from Amarin Pharma Inc.
    CME credit provided by the National Lipid Association
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Lipid Association and Medtelligence. The National Lipid Association is accredited by the ACCME to provide continuing medical education for physicians.
    The National Lipid Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
    Physician Assistants
    NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.
    The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1 Continuing Professional Education Units (CPEUs) for completion of this activity. CDR Accredited Provider #NL0002.
    CE Credit provided by Postgraduate Institute for Medicine
    Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    Universal Activity Number 0809-9999-15-252-H01-P (Application)
    Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education
    This educational activity for 1.2 contact hours is provided by the Postgraduate Institute for Medicine.
    Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
    Designated for 0.8 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
    Name Relationship Company
    Bays, Harold Consultant Amarin; Amgen; AstraZeneca; Bristol-Myers Squibb; Catabasis; Daiichi Sankyo, Inc.; Eisai; Eli Lilly; ISIS; Merck & Co., Inc.; Novartis; Novo Nordisk; Omthera; Pronovo; Sanofi; VIVUS; WPU
    Contracted Research Amarin; Amgen; Ardea Inc.; Arisaph; California Raisin Board; Catabasis; Eisai; Elcelyx; Eli Lilly; Esperion; Gilead; Hoffman LaRoche; Home Access; Janssen; Johnson & Johnson; Merck & Co., Inc.; Nektar; Novartis; Novo Nordisk; Omthera; Orexigen Therapeutics; Pfizer; Pronovo; Sanofi; Takeda; TIMI; Trygg Pharmaceuticals; VIVUS; WPU
    Speaker Amarin; Brisol-Myers Squibb; Daiichi Sakyo, Inc.; Eisai; Merck & Co., Inc.; Sanofi; VIVUS
    Libby, Peter Advisory Board Athera biotechnologies; Interleukin Genetics
    Consultant Amgen; AstraZeneca; Boehringer Ingleheim; Bristol-Myers Squibb; Eli Lilly and Company; Esperion Therapeutics; Genzyme; GlaxoSmithKline; ISIS Pharmaceuticals; KOWA Pharmaceuticals; Merck & Co., Inc.; Novartis; Pfizer; Sanofi-Regeneron; Takeda Pharmaceuticals
    Contracted Research General Electric; GlaxoSmithKline; Novartis
    Miller, Michael Consultant Amarin
    Medtelligence N/A Medtelligence planner Ben Caref, PhD, has Nothing to Disclose.
    NLA N/A Nothing to Disclose
    PIM N/A PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
    Wild, Robert Consultant Atherotech
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
    It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6+ for Mac OSX 10.7 and above

    For video playback, install the latest version of Flash or Quicktime.
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above